The FIB-4 score, which combines age, aspartate aminotransferase (AST) levels, platelet count, and alanine aminotransferase (ALT) levels, is a useful blood-based biomarker for evaluating and risk stratification of fibrosis without the need for a biopsy in patients with fatty liver disease. The gene discussed is GPT; the disease is fatty liver disease.